- Home
- PEGA vs BMRN Comparison
PEGA vs BMRN Comparison
Compare PEGA & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PEGA
- BMRN
- Stock Information
- Founded
- PEGA 1983
- BMRN 1996
- Country
- PEGA United States
- BMRN United States
- Employees
- PEGA N/A
- BMRN N/A
- Industry
- PEGA EDP Services
- BMRN Biotechnology: Pharmaceutical Preparations
- Sector
- PEGA Technology
- BMRN Health Care
- Exchange
- PEGA Nasdaq
- BMRN Nasdaq
- Market Cap
- PEGA 10.2B
- BMRN 11.1B
- IPO Year
- PEGA 1996
- BMRN 1999
- Fundamental
- Price
- PEGA $55.13
- BMRN $54.65
- Analyst Decision
- PEGA Buy
- BMRN Buy
- Analyst Count
- PEGA 11
- BMRN 20
- Target Price
- PEGA $60.45
- BMRN $92.21
- AVG Volume (30 Days)
- PEGA 1.4M
- BMRN 2.2M
- Earning Date
- PEGA 10-22-2025
- BMRN 10-28-2025
- Dividend Yield
- PEGA 0.11%
- BMRN N/A
- EPS Growth
- PEGA 61.54
- BMRN 154.69
- EPS
- PEGA 1.18
- BMRN 3.40
- Revenue
- PEGA $1,676,025,000.00
- BMRN $3,063,608,000.00
- Revenue This Year
- PEGA $16.35
- BMRN $13.35
- Revenue Next Year
- PEGA $6.37
- BMRN $9.18
- P/E Ratio
- PEGA $46.77
- BMRN $16.09
- Revenue Growth
- PEGA 12.47
- BMRN 18.36
- 52 Week Low
- PEGA $29.84
- BMRN $52.48
- 52 Week High
- PEGA $61.00
- BMRN $73.51
- Technical
- Relative Strength Index (RSI)
- PEGA 40.51
- BMRN 47.87
- Support Level
- PEGA $56.41
- BMRN $53.19
- Resistance Level
- PEGA $58.00
- BMRN $54.50
- Average True Range (ATR)
- PEGA 1.55
- BMRN 1.20
- MACD
- PEGA -0.24
- BMRN 0.29
- Stochastic Oscillator
- PEGA 16.36
- BMRN 62.43
About PEGA Pegasystems Inc.
Founded in 1983, Pegasystems provides a suite of solutions for customer engagement and business process management. The company's key offering is the Pega Infinity platform, which combines business process management with customer relationship management applications. The company focuses on enterprise-size customers in the financial, insurance, and healthcare industries.
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.